Aseries of disclosures in recent weeks revealed fraud and bribery in the Food and Drug Administration's (FDA) generic drug approval programs. Some lawmakers have reacted to these disturbing developments by calling for stricter FDA review of new drug approvals. FDA!sfeall problem, however, remains a drug approval process that moves too slowly, not too quickly. Over the past year, the FDA has taken several significant steps toward making new drugs available more quickly to those who need them most, such as sufferers of potentially fatal diseases, includ- ing AIDS. Only last week, for example, the FDA approved wide distribution of the anti-AIDS drug DDI, even though tests of the drug's effectiveness and side effects have not yet been com- pleted. The recent scandals should not be used as an excuse to halt or slow these actions.